Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2021
Reporting Period: Event-specific report regarding a legal settlement.
Key Financial Metrics
This filing is a current report regarding a legal settlement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material event is the resolution of U.S. patent litigation concerning the Company's product BIJUVA® (1 mg estradiol and 100 mg progesterone) with Amneal Pharmaceuticals, Inc. and related entities.
- Settlement Agreement: Entered into on December 7, 2021.
- Consent Judgment: Parties agreed to file a judgment enjoining Amneal from marketing a generic version of BIJUVA before patent expiration.
- License Grant: The Company granted Amneal a non-exclusive, non-transferable, royalty-free license to commercialize a generic formulation of BIJUVA in the U.S. commencing on May 25, 2032.
- Patent Expiration: The license start date is 180 days prior to the current expiration date of November 21, 2032, for the last-to-expire BIJUVA patents listed in the FDA Orange Book.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on December 8, 2021, announcing the settlement. The filing notes that the information in the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Risks and Contingencies: The settlement resolves previously disclosed patent litigation. The agreement includes provisions for the license to commence earlier under certain circumstances customary for such settlements.
Investor Verification Checklist
- Verify the specific terms of the consent judgment filed with the U.S. District Court for the District of New Jersey.
- Confirm the exact expiration dates of the BIJUVA patents listed in the FDA Orange Book.
- Review the full text of the Settlement Agreement (Exhibit 99.1) for details on "certain circumstances" that could trigger an earlier generic launch date.
- Assess the potential impact of the royalty-free license on future revenue projections for BIJUVA post-2032.